USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLETRAHYDROFOLATE FOR THE THEPARY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
Use of gestagen in combination with (6S)-5-methyltetrahydrofolate for the production of a pharmaceutical preparation (I) for the therapy of endometriosis with simultaneous reduction of therapy side-effects, preferably negative effects on bone density or bone metabolism, osteoporosis risk, risk of congenital malformations and pregnancy complications in early stage of pregnancy, is claimed, where the daily dose of the gestagen corresponds to at least an ovulation inhibiting dose to maximally dual of the ovulation inhibiting dose. ACTIVITY : Gynecological； Osteopathic. MECHANISM OF ACTION : None given.
